0.4942
Precedente Chiudi:
$0.5012
Aprire:
$0.518
Volume 24 ore:
134.71K
Relative Volume:
0.34
Capitalizzazione di mercato:
$19.26M
Reddito:
$9.44M
Utile/perdita netta:
$-7.58M
Rapporto P/E:
-0.4139
EPS:
-1.194
Flusso di cassa netto:
$-27.20M
1 W Prestazione:
+3.87%
1M Prestazione:
-16.96%
6M Prestazione:
-60.46%
1 anno Prestazione:
-75.29%
Curis Inc Stock (CRIS) Company Profile
Nome
Curis Inc
Settore
Industria
Telefono
617-503-6500
Indirizzo
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
CRIS
Curis Inc
|
0.4942 | 19.54M | 9.44M | -7.58M | -27.20M | -1.194 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-17 | Iniziato | Truist | Buy |
| 2022-04-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-03-25 | Iniziato | B. Riley Securities | Buy |
| 2020-07-29 | Iniziato | Laidlaw | Buy |
| 2020-07-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2016-03-02 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-08-11 | Iniziato | FBR Capital | Outperform |
| 2015-01-22 | Reiterato | Oppenheimer | Outperform |
| 2015-01-21 | Reiterato | ROTH Capital | Buy |
| 2014-05-09 | Reiterato | Oppenheimer | Outperform |
| 2013-10-02 | Iniziato | Robert W. Baird | Outperform |
| 2013-09-30 | Iniziato | Chardan Capital Markets | Buy |
| 2012-11-14 | Iniziato | Stifel Nicolaus | Hold |
| 2012-01-31 | Reiterato | Brean Murray | Buy |
| 2012-01-31 | Reiterato | Summer Street Research | Buy |
| 2011-12-09 | Iniziato | Oppenheimer | Outperform |
| 2011-10-06 | Iniziato | Summer Street Research | Buy |
| 2011-09-22 | Iniziato | MLV Capital | Buy |
| 2011-03-21 | Reiterato | Brean Murray | Buy |
| 2010-02-26 | Reiterato | Roth Capital | Buy |
| 2010-01-07 | Iniziato | Roth Capital | Buy |
Mostra tutto
Curis Inc Borsa (CRIS) Ultime notizie
Curis (NASDAQ: CRIS) wins shareholder approval to double authorized common stock - Stock Titan
CRIS News | CURIS INC (NASDAQ:CRIS) - ChartMill
Curis stock (US2312691006): Phase 1 data update lifts attention - AD HOC NEWS
Curis Inc Annual Shareholders Meeting Transcript - GuruFocus
CRIS: All five shareholder proposals, including director elections and share increase, were approved - TradingView
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Da - GuruFocus
Curis Faces Nasdaq Delisting Determination, Plans Appeal Hearing - TipRanks
Curis stock (US2312691006): cancer pipeline update keeps investors cautious - AD HOC NEWS
Armistice Capital (NASDAQ: CRIS) reports 4.99% ownership of Curis - Stock Titan
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Thomas Satterfield holds 3.96M shares as Curis (CRIS) ownership amended - Stock Titan
Curis, Inc. (NASDAQ:CRIS) Q1 2026 Earnings Call Transcript - Insider Monkey
Curis Q1 2026 earnings preview - MSN
Curis Inc. Earnings Call Highlights Clinical Momentum - TipRanks
Curis Q1 2026 Deep Dive: EPS Misses by 331.0%, Revenue Down 100% - AlphaStreet
Curis, Inc. (CRIS) Reports Q1 2026 Loss and Updates on Clinical Trials - GuruFocus
CURIS INC 1Q 2026: Revenue $0 Net income ($24.2M), EPS ($1.25) — 10-Q Summary - TradingView
Curis (NASDAQ: CRIS) posts larger Q1 2026 loss and warns on going concern - Stock Titan
Q1 2026 Curis Inc Earnings Call Transcript - GuruFocus
Curis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Curis anticipates TakeAim CLL initial 5-patient dosing by mid-2026 while projecting cash runway into second half of '27 - MSN
Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in L - GuruFocus
Curis (CRIS) Expects Sufficient Funding to Support Operations Un - GuruFocus
Earnings call transcript: Curis Q1 2026 reveals widened net loss - Investing.com UK
Curis (CRIS) Reports Q1 Revenue Below Expectations - GuruFocus
Curis Q1 2026 Earnings Call Transcript - MarketBeat
Curis (CRIS) Q1 Miss: EPS -$1.25 vs -$0.40 est, Revenue $0 vs $1 - GuruFocus
Curis Provides First Quarter 2026 Business Update - GuruFocus
Curis Sees Cash Runway Into the 2H of 2027 >CRIS - Moomoo
Earnings call transcript: Curis Q1 2026 reveals widened net loss By Investing.com - Investing.com Nigeria
Curis Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Curis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Curis reports Q1 loss, expects CLL trial milestone by mid-2026 - Investing.com South Africa
Curis: Q1 Earnings Snapshot - kens5.com
Curis (NASDAQ: CRIS) posts larger Q1 2026 loss and flags funding needs - Stock Titan
Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026 - Barchart
CRIS Q1'26 Earnings: EPS estimate is (0.33) USD - TradingView
Number of shareholders of Curis, Inc. – LSX:A3ETJD - TradingView
Curis Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds - Quantisnow
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 - Quantisnow
Curis Inc Azioni (CRIS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):